Eliran Moshe Reuven1, Shani Leviatan Ben-Arye1, Tal Marshanski1, Michael E Breimer2, Hai Yu3, Imen Fellah-Hebia4, Jean-Christian Roussel4, Cristina Costa5, Manuel Galiñanes6, Rafael Mañez5, Thierry Le Tourneau7, Jean-Paul Soulillou8, Emanuele Cozzi9, Xi Chen3, Vered Padler-Karavani10. 1. Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel. 2. Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. 3. Department of Chemistry, University of California-Davis, Davis, CA, USA. 4. Department of Thoracic and Cardiovascular Surgery, Institut du Thorax, University Hospital, Nantes, France. 5. Infectious Diseases and Transplantation Division, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. 6. Department of Cardiac Surgery, Reparative Therapy of the Heart, Hospital Universitari Vall d'Hebron and Vall d'Hebron Research Institute, Barcelona, Spain. 7. Department of Cardiology, Institut du Thorax, University Hospital, Nantes, France. 8. Institut de Transplantation-Urologie-Néphrologie, INSERM Unité Mixte de Recherche 1064, Centre Hospitalo Universitaire de Nantes, Nantes, France. 9. Transplant Immunology Unit, Department of Transfusion Medicine, Padua University Hospital, Padua, Italy. 10. Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel. vkaravani@post.tau.ac.il.
Abstract
BACKGROUND: The two common sialic acids (Sias) in mammals are N-acetylneuraminic acid (Neu5Ac) and its hydroxylated form N-glycolylneuraminic acid (Neu5Gc). Unlike most mammals, humans cannot synthesize Neu5Gc that is considered foreign and recognized by circulating antibodies. Thus, Neu5Gc is a potential xenogenic carbohydrate antigen in bioprosthetic heart valves (BHV) that tend to deteriorate in time within human patients. METHODS: We investigated Neu5Gc expression in non-engineered animal-derived cardiac tissues and in clinically used commercial BHV, and evaluated Neu5Gc immunogenicity on BHV through recognition by human anti-Neu5Gc IgG. RESULTS: Neu5Gc was detected by immunohistochemistry in porcine aortic valves and in porcine and bovine pericardium. Qualitative analysis of Sia linkages revealed Siaα2-3>Siaα2-6 on porcine/bovine pericardium while the opposite in porcine aortic/pulmonary valve cusps. Similarly, six commercial BHV containing either porcine aortic valve or porcine/bovine/equine pericardium revealed Siaα2-3>Siaα2-6 expression. Quantitative analysis of Sia by HPLC showed porcine/bovine pericardium express 4-fold higher Neu5Gc levels compared to the porcine aortic/pulmonary valves, with Neu5Ac at 6-fold over Neu5Gc. Likewise, Neu5Gc was expressed on commercial BHV (186.3±16.9 pmol Sia/μg protein), with Neu5Ac at 8-fold over Neu5Gc. Affinity-purified human anti-Neu5Gc IgG showing high specificity toward Neu5Gc-glycans (with no binding to Neu5Ac-glycans) on a glycan microarray, strongly bound to all tested commercial BHV, demonstrating Neu5Gc immune recognition in cardiac xenografts. CONCLUSIONS: We conclusively demonstrated Neu5Gc expression in native cardiac tissues, as well as in six commercial BHV. These Neu5Gc xeno-antigens were recognized by human anti-Neu5Gc IgG, supporting their immunogenicity. Altogether, these findings suggest BHV-Neu5Gc/anti-Neu5Gc may play a role in valve deterioration warranting further investigation.
BACKGROUND: The two common sialic acids (Sias) in mammals are N-acetylneuraminic acid (Neu5Ac) and its hydroxylated form N-glycolylneuraminic acid (Neu5Gc). Unlike most mammals, humans cannot synthesize Neu5Gc that is considered foreign and recognized by circulating antibodies. Thus, Neu5Gc is a potential xenogenic carbohydrate antigen in bioprosthetic heart valves (BHV) that tend to deteriorate in time within humanpatients. METHODS: We investigated Neu5Gc expression in non-engineered animal-derived cardiac tissues and in clinically used commercial BHV, and evaluated Neu5Gc immunogenicity on BHV through recognition by human anti-Neu5Gc IgG. RESULTS:Neu5Gc was detected by immunohistochemistry in porcine aortic valves and in porcine and bovine pericardium. Qualitative analysis of Sia linkages revealed Siaα2-3>Siaα2-6 on porcine/bovine pericardium while the opposite in porcine aortic/pulmonary valve cusps. Similarly, six commercial BHV containing either porcine aortic valve or porcine/bovine/equine pericardium revealed Siaα2-3>Siaα2-6 expression. Quantitative analysis of Sia by HPLC showed porcine/bovine pericardium express 4-fold higher Neu5Gc levels compared to the porcine aortic/pulmonary valves, with Neu5Ac at 6-fold over Neu5Gc. Likewise, Neu5Gc was expressed on commercial BHV (186.3±16.9 pmol Sia/μg protein), with Neu5Ac at 8-fold over Neu5Gc. Affinity-purified human anti-Neu5Gc IgG showing high specificity toward Neu5Gc-glycans (with no binding to Neu5Ac-glycans) on a glycan microarray, strongly bound to all tested commercial BHV, demonstrating Neu5Gc immune recognition in cardiac xenografts. CONCLUSIONS: We conclusively demonstrated Neu5Gc expression in native cardiac tissues, as well as in six commercial BHV. These Neu5Gc xeno-antigens were recognized by human anti-Neu5Gc IgG, supporting their immunogenicity. Altogether, these findings suggest BHV-Neu5Gc/anti-Neu5Gc may play a role in valve deterioration warranting further investigation.
Authors: Douglas R Johnston; Edward G Soltesz; Nakul Vakil; Jeevanantham Rajeswaran; Eric E Roselli; Joseph F Sabik; Nicholas G Smedira; Lars G Svensson; Bruce W Lytle; Eugene H Blackstone Journal: Ann Thorac Surg Date: 2015-02-04 Impact factor: 4.330
Authors: Guerard W Byrne; Paul G Stalboerger; Zeji Du; Tessa R Davis; Christopher G A McGregor Journal: Transplantation Date: 2011-02-15 Impact factor: 4.939
Authors: Sandra L Diaz; Vered Padler-Karavani; Darius Ghaderi; Nancy Hurtado-Ziola; Hai Yu; Xi Chen; Els C M Brinkman-Van der Linden; Ajit Varki; Nissi M Varki Journal: PLoS One Date: 2009-01-21 Impact factor: 3.240
Authors: Wendy F Li; Heidi Pollard; Mohsen Karimi; Jeremy D Asnes; William E Hellenbrand; Veronika Shabanova; Constance G Weismann Journal: Congenit Heart Dis Date: 2017-11-17 Impact factor: 2.007
Authors: Shani Leviatan Ben-Arye; Christoph Schneider; Hai Yu; Salam Bashir; Xi Chen; Stephan von Gunten; Vered Padler-Karavani Journal: Bioconjug Chem Date: 2019-04-24 Impact factor: 4.774
Authors: Annie N Samraj; Kimberly A Bertrand; Robert Luben; Zahra Khedri; Hai Yu; Dzung Nguyen; Christopher J Gregg; Sandra L Diaz; Sherilyn Sawyer; Xi Chen; Heather Eliassen; Vered Padler-Karavani; Kana Wu; Kay-Tee Khaw; Walter Willett; Ajit Varki Journal: PLoS One Date: 2018-06-18 Impact factor: 3.240